NASDAQ:CYTO Altamira Therapeutics (CYTO) Stock Price, News & Analysis → A once-in-a-century investment opportunity (From Stansberry Research) (Ad) Free CYTO Stock Alerts $1.56 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.51▼$1.5650-Day Range$1.40▼$2.4252-Week Range$1.35▼$23.60Volume20,122 shsAverage Volume830,317 shsMarket Capitalization$2.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Altamira Therapeutics alerts: Email Address Ad Stansberry ResearchThe Presidential candidate you should REALLY be worried aboutThe Presidential candidate you should REALLY be worried about Most Americans are overlooking the seemingly impossible candidate that should worry you. It's not Biden… Trump… Newsom… or even Michelle. It's someone even worse. New evidence of a secret plan indicates he could soon return, and finish what he started.Get the full story right here. About Altamira Therapeutics Stock (NASDAQ:CYTO)Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Read More CYTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTO Stock News HeadlinesMay 12, 2024 | americanbankingnews.comShort Interest in Altamira Therapeutics Ltd. (NASDAQ:CYTO) Expands By 67.5%May 1, 2024 | globenewswire.comAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationApril 24, 2024 | msn.comAltamira reports publication of positive results from NASAR clinical trial with BentrioApril 24, 2024 | globenewswire.comAltamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalApril 15, 2024 | finance.yahoo.comDiamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)April 12, 2024 | seekingalpha.comAltamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call TranscriptApril 12, 2024 | msn.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call TranscriptApril 10, 2024 | finance.yahoo.comAltamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsApril 4, 2024 | globenewswire.comAltamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024March 26, 2024 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesMarch 26, 2024 | markets.businessinsider.comCrude Oil Moves Higher; US New Home Sales Fall In FebruaryMarch 25, 2024 | msn.comWhy Altamira Therapeutics Stock Is Racing HigherMarch 25, 2024 | msn.comAltamira stock rallies 44% on Univercells mRNA collaborationMarch 25, 2024 | globenewswire.comAltamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesFebruary 7, 2024 | finance.yahoo.comAltamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalJanuary 24, 2024 | marketwatch.comAltamira Therapeutics Shares Rise 13% After Filing Second Provisional Patent ApplicationJanuary 24, 2024 | msn.comAltamira Therapeutics stock jumps 7% as it files for second patentJanuary 24, 2024 | finance.yahoo.comAltamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentJanuary 8, 2024 | finance.yahoo.comAltamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitDecember 29, 2023 | finance.yahoo.comAltamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementDecember 11, 2023 | msn.comAltamira shares sink over 40% on corporate, stock split updatesDecember 11, 2023 | msn.comWhy Altamira Therapeutics (CYTO) Stock Is Down 50% TodayDecember 11, 2023 | finance.yahoo.comAltamira Therapeutics Provides Investor and Business UpdateDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thSee More Headlines Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/17/2024Next Earnings (Estimated)7/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTO CUSIPN/A CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950Fax41-61-201-1351Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$320,000.00 Price / Sales7.60 Cash FlowN/A Price / Cash FlowN/A Book Value$4.56 per share Price / Book0.34Miscellaneous Outstanding Shares1,580,000Free Float1,372,000Market Cap$2.43 million OptionableNot Optionable Beta1.82 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Thomas Meyer Ph.D. (Age 56)Founder, President, Chairman, CEO & MD Comp: $552.7kDr. Covadonga Paneda (Age 50)Chief Operating Officer Dr. Samuel A. Wickline M.D. (Age 71)Chief Scientific Adviser Key CompetitorsAvenue TherapeuticsNASDAQ:ATXIDermata TherapeuticsNASDAQ:DRMASalarius PharmaceuticalsNASDAQ:SLRXSonoma PharmaceuticalsNASDAQ:SNOAClearmind MedicineNASDAQ:CMNDView All Competitors CYTO Stock Analysis - Frequently Asked Questions How have CYTO shares performed in 2024? Altamira Therapeutics' stock was trading at $3.48 on January 1st, 2024. Since then, CYTO stock has decreased by 55.2% and is now trading at $1.56. View the best growth stocks for 2024 here. When is Altamira Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our CYTO earnings forecast. When did Altamira Therapeutics' stock split? Shares of Altamira Therapeutics reverse split on Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Altamira Therapeutics' major shareholders? Altamira Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Altamira Therapeutics? Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTO) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchShocking $16T Elon Musk Crypto LeakCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlace[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
